Micol Rothman
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteoporosis | 10 | 2023 | 231 | 4.050 |
Why?
| Transgender Persons | 5 | 2024 | 172 | 2.620 |
Why?
| Osteoporotic Fractures | 5 | 2024 | 57 | 2.560 |
Why?
| Bone Density Conservation Agents | 9 | 2024 | 70 | 2.310 |
Why?
| Absorptiometry, Photon | 5 | 2023 | 246 | 1.340 |
Why?
| Transsexualism | 2 | 2021 | 19 | 1.330 |
Why?
| Bone Density | 6 | 2022 | 463 | 1.090 |
Why?
| Bone Diseases, Metabolic | 3 | 2024 | 57 | 1.060 |
Why?
| Hyperandrogenism | 2 | 2021 | 19 | 1.050 |
Why?
| Estradiol | 3 | 2024 | 492 | 1.000 |
Why?
| Postmenopause | 4 | 2021 | 349 | 0.770 |
Why?
| Testosterone | 5 | 2024 | 371 | 0.740 |
Why?
| Interdisciplinary Placement | 1 | 2020 | 2 | 0.680 |
Why?
| Sexual and Gender Minorities | 1 | 2023 | 196 | 0.650 |
Why?
| Videoconferencing | 1 | 2020 | 64 | 0.650 |
Why?
| Telecommunications | 1 | 2019 | 20 | 0.640 |
Why?
| Practice Guidelines as Topic | 2 | 2019 | 1510 | 0.620 |
Why?
| Education, Medical, Continuing | 1 | 2020 | 121 | 0.620 |
Why?
| Clinical Decision-Making | 1 | 2019 | 304 | 0.520 |
Why?
| Diphosphonates | 2 | 2019 | 58 | 0.490 |
Why?
| Quality Improvement | 1 | 2023 | 1103 | 0.480 |
Why?
| Pneumonia, Viral | 1 | 2020 | 342 | 0.480 |
Why?
| Coronavirus Infections | 1 | 2020 | 336 | 0.470 |
Why?
| Hypogonadism | 3 | 2013 | 84 | 0.470 |
Why?
| Denosumab | 3 | 2024 | 8 | 0.440 |
Why?
| Mass Media | 1 | 2014 | 40 | 0.440 |
Why?
| Glucocorticoids | 3 | 2024 | 583 | 0.420 |
Why?
| Osteoporosis, Postmenopausal | 2 | 2024 | 39 | 0.410 |
Why?
| Estrone | 2 | 2010 | 37 | 0.380 |
Why?
| Telemedicine | 1 | 2020 | 792 | 0.360 |
Why?
| Spinal Fractures | 2 | 2024 | 84 | 0.360 |
Why?
| Mass Screening | 2 | 2021 | 1186 | 0.360 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 267 | 0.350 |
Why?
| Polycystic Ovary Syndrome | 1 | 2013 | 164 | 0.350 |
Why?
| Fibrous Dysplasia, Polyostotic | 1 | 2010 | 7 | 0.350 |
Why?
| Dihydrotestosterone | 1 | 2010 | 41 | 0.350 |
Why?
| Humans | 33 | 2024 | 129527 | 0.340 |
Why?
| Facial Bones | 1 | 2010 | 28 | 0.340 |
Why?
| Menstrual Cycle | 1 | 2010 | 121 | 0.330 |
Why?
| Skull | 1 | 2010 | 130 | 0.320 |
Why?
| Gender Identity | 2 | 2021 | 118 | 0.320 |
Why?
| Hypothalamo-Hypophyseal System | 2 | 2024 | 180 | 0.310 |
Why?
| Female | 17 | 2024 | 68650 | 0.280 |
Why?
| Infertility | 1 | 2007 | 49 | 0.270 |
Why?
| Neurosecretory Systems | 1 | 2007 | 31 | 0.270 |
Why?
| Ovary | 1 | 2008 | 209 | 0.250 |
Why?
| Male | 16 | 2024 | 63586 | 0.250 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2007 | 203 | 0.250 |
Why?
| Bone Remodeling | 1 | 2024 | 71 | 0.220 |
Why?
| Adult | 11 | 2024 | 35505 | 0.220 |
Why?
| Injections, Subcutaneous | 1 | 2024 | 146 | 0.220 |
Why?
| Injections, Intramuscular | 1 | 2024 | 117 | 0.220 |
Why?
| Adrenal Insufficiency | 1 | 2024 | 32 | 0.210 |
Why?
| Cohort Studies | 2 | 2023 | 5423 | 0.200 |
Why?
| Thromboembolism | 1 | 2024 | 112 | 0.200 |
Why?
| Brain Injuries | 1 | 2007 | 469 | 0.190 |
Why?
| Academic Medical Centers | 1 | 2023 | 478 | 0.170 |
Why?
| Androgens | 2 | 2013 | 177 | 0.170 |
Why?
| Hydrocortisone | 2 | 2024 | 306 | 0.170 |
Why?
| Hormones | 1 | 2021 | 140 | 0.170 |
Why?
| Osteitis Deformans | 1 | 2020 | 4 | 0.170 |
Why?
| Aged | 7 | 2024 | 22063 | 0.160 |
Why?
| Self Administration | 1 | 2020 | 122 | 0.160 |
Why?
| Prostatic Neoplasms | 1 | 2007 | 995 | 0.160 |
Why?
| Osteolysis | 1 | 2020 | 18 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 1 | 2024 | 2013 | 0.160 |
Why?
| Fractures, Compression | 1 | 2020 | 19 | 0.160 |
Why?
| Comprehensive Health Care | 1 | 2019 | 21 | 0.160 |
Why?
| Pyrazoles | 2 | 2013 | 403 | 0.160 |
Why?
| Health Services for the Aged | 1 | 2019 | 72 | 0.160 |
Why?
| Self Report | 1 | 2023 | 800 | 0.150 |
Why?
| Pyridines | 2 | 2013 | 478 | 0.150 |
Why?
| House Calls | 1 | 2020 | 124 | 0.150 |
Why?
| Bone and Bones | 1 | 2021 | 295 | 0.150 |
Why?
| Hip Fractures | 1 | 2019 | 83 | 0.150 |
Why?
| Referral and Consultation | 1 | 2023 | 732 | 0.150 |
Why?
| Spinal Stenosis | 1 | 2018 | 27 | 0.150 |
Why?
| HIV Infections | 1 | 2012 | 2729 | 0.140 |
Why?
| Anorexia Nervosa | 1 | 2019 | 83 | 0.140 |
Why?
| Progesterone | 1 | 2019 | 244 | 0.140 |
Why?
| Aged, 80 and over | 4 | 2023 | 7052 | 0.140 |
Why?
| Anesthetics, Local | 1 | 2018 | 79 | 0.140 |
Why?
| Back Pain | 1 | 2018 | 53 | 0.140 |
Why?
| Betacoronavirus | 1 | 2020 | 252 | 0.140 |
Why?
| Curriculum | 1 | 2023 | 922 | 0.130 |
Why?
| Protein Kinase Inhibitors | 2 | 2013 | 885 | 0.130 |
Why?
| Pelvic Bones | 1 | 2019 | 156 | 0.130 |
Why?
| Diagnosis, Differential | 2 | 2011 | 1422 | 0.120 |
Why?
| Sexual Behavior | 1 | 2019 | 481 | 0.120 |
Why?
| Retrospective Studies | 5 | 2024 | 14532 | 0.110 |
Why?
| Adrenal Cortex Hormones | 1 | 2018 | 535 | 0.110 |
Why?
| Teriparatide | 2 | 2024 | 6 | 0.110 |
Why?
| Primary Health Care | 1 | 2023 | 1677 | 0.100 |
Why?
| Middle Aged | 9 | 2020 | 31087 | 0.100 |
Why?
| Delivery of Health Care | 1 | 2020 | 896 | 0.100 |
Why?
| Surveys and Questionnaires | 2 | 2023 | 5429 | 0.100 |
Why?
| Pandemics | 1 | 2020 | 1500 | 0.090 |
Why?
| Hirsutism | 1 | 2011 | 12 | 0.090 |
Why?
| Antineoplastic Agents | 2 | 2013 | 2044 | 0.090 |
Why?
| Prevalence | 2 | 2019 | 2561 | 0.090 |
Why?
| Injections, Intravenous | 1 | 2010 | 202 | 0.080 |
Why?
| Imidazoles | 1 | 2010 | 235 | 0.080 |
Why?
| Quality of Life | 1 | 2021 | 2694 | 0.080 |
Why?
| Reference Values | 1 | 2010 | 795 | 0.080 |
Why?
| Chromatography, Liquid | 1 | 2010 | 424 | 0.080 |
Why?
| Pituitary Hormones | 1 | 2008 | 16 | 0.070 |
Why?
| Amenorrhea | 1 | 2008 | 27 | 0.070 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2012 | 353 | 0.070 |
Why?
| Kisspeptins | 1 | 2007 | 5 | 0.070 |
Why?
| Thyroid Hormones | 1 | 2008 | 55 | 0.070 |
Why?
| Endocrine Glands | 1 | 2007 | 15 | 0.070 |
Why?
| Tandem Mass Spectrometry | 1 | 2010 | 525 | 0.070 |
Why?
| Pituitary Hormones, Anterior | 1 | 2007 | 7 | 0.070 |
Why?
| Pituitary Gland, Anterior | 1 | 2007 | 39 | 0.070 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 1050 | 0.070 |
Why?
| Hypothalamus | 1 | 2007 | 148 | 0.070 |
Why?
| Prolactin | 1 | 2007 | 97 | 0.070 |
Why?
| Gonadal Steroid Hormones | 1 | 2008 | 131 | 0.060 |
Why?
| Thyrotropin | 1 | 2007 | 107 | 0.060 |
Why?
| Adrenocorticotropic Hormone | 1 | 2007 | 133 | 0.060 |
Why?
| Incidence | 1 | 2012 | 2643 | 0.060 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2007 | 206 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2007 | 311 | 0.060 |
Why?
| Withholding Treatment | 1 | 2024 | 71 | 0.060 |
Why?
| Endocrinologists | 1 | 2024 | 12 | 0.050 |
Why?
| Pituitary-Adrenal System | 1 | 2024 | 147 | 0.050 |
Why?
| Lumbar Vertebrae | 1 | 2024 | 234 | 0.050 |
Why?
| Parathyroid Hormone-Related Protein | 1 | 2022 | 24 | 0.050 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2020 | 8 | 0.040 |
Why?
| RANK Ligand | 1 | 2020 | 26 | 0.040 |
Why?
| Young Adult | 2 | 2019 | 12438 | 0.040 |
Why?
| Calcium, Dietary | 1 | 2019 | 56 | 0.040 |
Why?
| Adolescent | 2 | 2019 | 20409 | 0.040 |
Why?
| Risk Factors | 1 | 2012 | 9779 | 0.040 |
Why?
| Health Status | 1 | 2024 | 756 | 0.040 |
Why?
| Triamcinolone | 1 | 2018 | 15 | 0.040 |
Why?
| Injections, Epidural | 1 | 2018 | 19 | 0.040 |
Why?
| Betamethasone | 1 | 2018 | 20 | 0.040 |
Why?
| Lidocaine | 1 | 2018 | 41 | 0.040 |
Why?
| Methylprednisolone | 1 | 2018 | 83 | 0.040 |
Why?
| Disease Progression | 1 | 2024 | 2628 | 0.030 |
Why?
| Vitamin D Deficiency | 1 | 2019 | 177 | 0.030 |
Why?
| Survival Analysis | 1 | 2019 | 1270 | 0.030 |
Why?
| Double-Blind Method | 2 | 2018 | 1873 | 0.030 |
Why?
| Eating | 1 | 2019 | 371 | 0.030 |
Why?
| Dexamethasone | 1 | 2018 | 347 | 0.030 |
Why?
| Estrogen Replacement Therapy | 1 | 1996 | 137 | 0.030 |
Why?
| Vitamin D | 1 | 2019 | 379 | 0.030 |
Why?
| Pain Measurement | 1 | 2018 | 507 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2022 | 1366 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 1037 | 0.030 |
Why?
| Body Composition | 1 | 2019 | 649 | 0.030 |
Why?
| Pain Management | 1 | 2018 | 330 | 0.030 |
Why?
| Electronic Health Records | 1 | 2022 | 977 | 0.030 |
Why?
| Signal Transduction | 1 | 2007 | 4916 | 0.030 |
Why?
| Biomarkers | 1 | 2024 | 3968 | 0.030 |
Why?
| Sex Hormone-Binding Globulin | 1 | 2013 | 53 | 0.030 |
Why?
| Funnel Chest | 1 | 2012 | 25 | 0.020 |
Why?
| Adipokines | 1 | 2012 | 47 | 0.020 |
Why?
| Luteinizing Hormone | 1 | 2013 | 178 | 0.020 |
Why?
| Serum Albumin | 1 | 2013 | 149 | 0.020 |
Why?
| Ethanol | 1 | 1996 | 591 | 0.020 |
Why?
| Follicle Stimulating Hormone | 1 | 2013 | 237 | 0.020 |
Why?
| Disease Susceptibility | 1 | 2012 | 333 | 0.020 |
Why?
| Alcohol Drinking | 1 | 1996 | 764 | 0.020 |
Why?
| Scoliosis | 1 | 2012 | 199 | 0.020 |
Why?
| Neoplasm Metastasis | 1 | 2012 | 609 | 0.020 |
Why?
| Adipose Tissue | 1 | 2012 | 594 | 0.020 |
Why?
| Colorectal Neoplasms | 1 | 2013 | 744 | 0.020 |
Why?
| Case-Control Studies | 1 | 2012 | 3383 | 0.010 |
Why?
| Animals | 1 | 2007 | 35334 | 0.010 |
Why?
| Cytokines | 1 | 2012 | 2018 | 0.010 |
Why?
| Body Mass Index | 1 | 2012 | 2269 | 0.010 |
Why?
| Phenotype | 1 | 2012 | 3058 | 0.010 |
Why?
| Treatment Outcome | 1 | 2018 | 10232 | 0.010 |
Why?
| Lung Neoplasms | 1 | 2013 | 2342 | 0.010 |
Why?
| Medroxyprogesterone Acetate | 1 | 1996 | 35 | 0.010 |
Why?
| Cross-Over Studies | 1 | 1996 | 522 | 0.010 |
Why?
|
|
Rothman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|